In vivo resistance of a laboratory-selected Aspergillus fumigatus isolate to amphotericin B.
The fungal burdens (number of CFU per pair of lungs) in mice infected with Aspergillus fumigatus AB16.4 (for which the amphotericin B [AMB] MIC was elevated) and W73355 (drug-susceptible parent) were reduced by 21 and 81%, respectively, after 5 days of AMB treatment (2 mg/kg/day), indicating that AB16.4 also shows reduced susceptibility to AMB in a murine pulmonary aspergillosis model.
Manavathu
Elias K
EK
Department of Internal Medicine, 427 Lande Building, Wayne State University, 550 E. Canfield, Detroit, MI 48201, USA. aa1388@wayne.edu
Cutright
Jessica L
JL
Chandrasekar
Pranatharthi H
PH
D000666:Amphotericin B / Q000494:pharmacology / Q000627:therapeutic use*; D000818:Animals; D000935:Antifungal Agents / Q000494:pharmacology / Q000627:therapeutic use*; D001228:Aspergillosis / Q000188:drug therapy / Q000382:microbiology; D001232:Aspergillus fumigatus / Q000187:drug effects* / Q000302:isolation & purification; D015169:Colony Count, Microbial; D004195:Disease Models, Animal; D024881:Drug Resistance, Bacterial; D005260:Female; D006801:Humans; D007753:Laboratories; D008168:Lung / Q000382:microbiology*; D008172:Lung Diseases, Fungal / Q000188:drug therapy* / Q000382:microbiology; D051379:Mice; D008811:Mice, Inbred DBA
D000935:Antifungal Agents; D000666:Amphotericin B